2269.HK vs. ^HSI

Last updated Jun 5, 2026

2269.HK (WuXi Biologics) is a stock, while ^HSI (Hang Seng Index) is an index. Over the past 5 years, 2269.HK returned -23.17%/yr vs -2.67%/yr for ^HSI. A 0.56 correlation means they provide meaningful diversification when combined.

Performance

2269.HK vs. ^HSI - Performance Comparison

The chart below illustrates the hypothetical performance of a HK$10,000 investment in WuXi Biologics (2269.HK) and Hang Seng Index (^HSI). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, 2269.HK achieves a 3.12% return, which is significantly higher than ^HSI's -1.47% return.

2269.HK

• 1D: -0.80%
• 1M: -1.70%
• YTD: 3.12%
• 6M: -0.61%
• 1Y: 30.20%
• 3Y*: -9.58%
• 5Y*: -23.17%
• 10Y*: —

^HSI

• 1D: -1.48%
• 1M: -2.49%
• YTD: -1.47%
• 6M: -2.63%
• 1Y: 6.76%
• 3Y*: 9.74%
• 5Y*: -2.67%
• 10Y*: 1.85%

*Multi-year figures are annualized to reflect compound growth (CAGR)

2269.HK vs. ^HSI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
2269.HK WuXi Biologics	3.12%	78.64%	-40.54%	-50.54%	-35.33%	-9.26%	210.19%	96.71%	14.76%	54.69%
^HSI Hang Seng Index	-1.47%	27.77%	17.67%	-13.82%	-15.46%	-14.08%	-3.40%	9.07%	-13.61%	15.73%

Correlation

The correlation between 2269.HK and ^HSI is 0.57, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.57
Correlation (3Y) Calculated over the trailing 3-year period	0.62
Correlation (5Y) Calculated over the trailing 5-year period	0.63
Correlation (All Time) Calculated using the full available price history since Jun 14, 2017	0.56

The correlation between 2269.HK and ^HSI has been stable across timeframes, ranging from 0.56 to 0.63 - a consistent structural relationship.

Return for Risk

2269.HK vs. ^HSI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

2269.HK

2269.HK Risk / Return Rank: 60
2269.HK Sharpe Ratio Rank: 63
2269.HK Sortino Ratio Rank: 59
2269.HK Omega Ratio Rank: 55
2269.HK Calmar Ratio Rank: 63
2269.HK Martin Ratio Rank: 60

^HSI

^HSI Risk / Return Rank: 27
^HSI Sharpe Ratio Rank: 27
^HSI Sortino Ratio Rank: 26
^HSI Omega Ratio Rank: 25
^HSI Calmar Ratio Rank: 28
^HSI Martin Ratio Rank: 29

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

2269.HK vs. ^HSI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for WuXi Biologics (2269.HK) and Hang Seng Index (^HSI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	2269.HK	^HSI	Difference
Sharpe ratio: Return per unit of total volatility	0.65	0.37	+0.27
Sortino ratio: Return per unit of downside risk	1.20	0.67	+0.53
Omega ratio: Gain probability vs. loss probability	1.14	1.07	+0.06
Calmar ratio: Return relative to maximum drawdown	1.07	0.54	+0.53
Martin ratio: Return relative to average drawdown	1.98	1.35	+0.64
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

2269.HK vs. ^HSI - Sharpe Ratio Comparison

The current 2269.HK Sharpe Ratio is 0.65, which is higher than the ^HSI Sharpe Ratio of 0.37. The chart below compares the historical Sharpe Ratios of 2269.HK and ^HSI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	2269.HK	^HSI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.65	0.37	+0.27
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.36	-0.11	-0.25
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.09	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.25	0.27	-0.01

Drawdowns

2269.HK vs. ^HSI - Drawdown Comparison

The maximum 2269.HK drawdown since its inception was -92.95%, which is greater than ^HSI's maximum drawdown of -65.18%. Use the drawdown chart below to compare losses from any high point for 2269.HK and ^HSI.

Drawdown Indicators

	2269.HK	^HSI	Difference
Max Drawdown Largest peak-to-trough decline	-92.95%	-65.18%	-27.77%
Max Drawdown (1Y) Largest decline over 1 year	-27.55%	-12.82%	-14.73%
Max Drawdown (3Y) Largest decline over 3 years	-79.88%	-25.49%	-54.39%
Max Drawdown (5Y) Largest decline over 5 years	-92.95%	-49.85%	-43.10%
Max Drawdown (10Y) Largest decline over 10 years	—	-55.70%	—
Current Drawdown Current decline from peak	-77.73%	-23.83%	-53.90%
Average Drawdown Average peak-to-trough decline	-42.93%	-24.17%	-18.76%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.69%	5.09%	+9.60%

Volatility

2269.HK vs. ^HSI - Volatility Comparison

WuXi Biologics (2269.HK) has a higher volatility of 13.26% compared to Hang Seng Index (^HSI) at 5.18%. This indicates that 2269.HK's price experiences larger fluctuations and is considered to be riskier than ^HSI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	2269.HK	^HSI	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.26%	5.18%	+8.08%
Volatility (6M) Calculated over the trailing 6-month period	31.29%	13.70%	+17.59%
Volatility (1Y) Calculated over the trailing 1-year period	45.42%	18.52%	+26.90%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	66.73%	25.32%	+41.41%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	60.03%	21.96%	+38.07%

Frequently Asked Questions

Can I hold both 2269.HK and ^HSI in my portfolio?

2269.HK and ^HSI have a correlation of 0.57, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.